GRI Bio Inc. announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,528,775, granting composition-of-matter claims for a new class of proprietary compounds featuring pyrrolidine, piperidine, or azepane ring systems. The patent provides additional intellectual property protection for the company's platform of immunomodulators aimed at inflammatory, fibrotic, and autoimmune diseases. According to GRI Bio, this newly issued patent strengthens the company's IP estate by securing independent protection for a unique subset of its chemistry platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9642033) on January 26, 2026, and is solely responsible for the information contained therein.